Opiate analgesics
Executive Summary
FDA's Anesthetic & Life Support Drugs Advisory Committee will discuss the benefits and risks of the medical use of opiate analgesics in pediatric patients and patients with chronic pain of nonmalignant etiology Sept. 13 and 14. The committee will also address concerns regarding abuse potential, diversion and increase of addiction to modified release opiate analgesics. Purdue Pharma has developed an education program to prevent abuse of its controlled-release oxycodone product OxyContin. The meeting will begin at 8 a.m. both days at the University of Maryland-Shady Grove. An advisory committee meeting on the topics had been scheduled for June 14-15